Sigh. I really thought we would have some new stuff to chat about now that it is September 2023. I mean, you know, besides Brent Saunders.
It is once again time for us to look at the state of anti-inflammatory treatment in the dry eye disease (DED) world. This category is simultaneously the cornerstone of both DED treatment and the commercial world that surrounds us and our DED patients. It has been this way since the approval of Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) in the early aughts and for (Read more...)